Avalo Therapeutics (AVTX) Receivables - Net (2016 - 2023)

Avalo Therapeutics has reported Receivables - Net for 8 years, with the latest figure at $38000.0 in Q2 2023.

• For the quarter ending Q2 2023, Receivables - Net fell 93.01% year-over-year to $38000.0; the trailing twelve-month figure through Jun 2023 stood at $38000.0 (down 93.01% YoY), and the FY2021 full-year result was $1.1 million, down 51.31% from the prior year.
• Receivables - Net for Q2 2023 stood at $38000.0, down from $544000.0 in the prior quarter.
• The five-year high for Receivables - Net was $5.0 million in Q3 2019, with the low at $38000.0 in Q2 2023.
• Historically, Receivables - Net has averaged $2.1 million across 5 years, with a median of $2.0 million in 2020.
• Annual changes were most pronounced in 2020 — Receivables - Net surged 117.34% — and 2023, when it sank 93.01%.
• Avalo Therapeutics' Receivables - Net stood at $1.0 million in 2019, then soared by 117.34% to $2.2 million in 2020, then tumbled by 51.31% to $1.1 million in 2021, then sank by 48.68% to $544000.0 in 2022, then slumped by 93.01% to $38000.0 in 2023.
• The last three Receivables - Net figures came in at $38000.0 (Q2 2023), $544000.0 (Q2 2022), and $938000.0 (Q1 2022), per Business Quant data.